Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression - PubMed (original) (raw)
Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression
S Duty et al. Exp Neurol. 1997 Apr.
Abstract
Repeated dopamine receptor stimulation in the 6-hydroxydopamine (6-OHDA)-lesioned rat produces a marked enhancement in the behavioral response to a given dose of dopamine agonist. Such treatment also increases the synthesis of preproenkephalin-B (PPE-B) throughout the striatum and preproenkephalin-A (PPE-A) rostrally. To examine the relationship between these changes, 6-OHDA-lesioned rats were treated with apomorphine (5 mg/kg) twice-daily. Between 0.5 and 7 days treatment, behavior was monitored and the levels of PPE-A and PPE-B mRNA were determined by in situ hybridization. A single injection of apomorphine induced a well-known rotational response contraversive to the lesion (314 +/- 22 rotations h-1). However, with repeated injection, the response to apomorphine was markedly enhanced, being significantly higher on Days 3 (704 +/- 60 rotations h-1), 5 (1354 +/- 104 rotations h-1), and 7 (1680 +/- 117 rotations h-1). In the lesioned caudate-putamen, but not in the nucleus accumbens, PPE-B expression rose in a manner that was temporally correlated with the enhanced locomotor response to apomorphine. PPE-A expression in the lesioned striatum, significantly increased only after 7 days treatment, did not correlate with the behavioral response. In conclusion, PPE-B may contribute to the development of behavioral supersensitivity following repeated dopamine-replacement therapy in animal models of Parkinson's disease.
Similar articles
- Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.
Duty S, Henry B, Crossman AR, Brotchie JM. Duty S, et al. Exp Neurol. 1998 Apr;150(2):223-34. doi: 10.1006/exnr.1997.6771. Exp Neurol. 1998. PMID: 9527891 - Pharmacologic regulation of striatal proenkephalin gene expression via transcription factor CREB.
Hyman SE, Konradi C, Kobierski L, Cole R, Senatus P, Green D. Hyman SE, et al. Prog Clin Biol Res. 1994;390:155-71. Prog Clin Biol Res. 1994. PMID: 7724644 Review. No abstract available.
Cited by
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.
Yue X, Falk T, Zuniga LA, Szabò L, Porreca F, Polt R, Sherman SJ. Yue X, et al. Brain Res. 2011 Sep 21;1413:72-83. doi: 10.1016/j.brainres.2011.07.038. Epub 2011 Jul 23. Brain Res. 2011. PMID: 21840512 Free PMC article. - The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. Flores AJ, et al. Neuropharmacology. 2018 Oct;141:260-271. doi: 10.1016/j.neuropharm.2018.09.005. Epub 2018 Sep 7. Neuropharmacology. 2018. PMID: 30201210 Free PMC article. - CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.
Mabrouk OS, Falk T, Sherman SJ, Kennedy RT, Polt R. Mabrouk OS, et al. Neurosci Lett. 2012 Dec 7;531(2):99-103. doi: 10.1016/j.neulet.2012.10.029. Epub 2012 Nov 2. Neurosci Lett. 2012. PMID: 23127847 Free PMC article.